Skip to content
ESMO Poster 2024

Document -

ESMO Poster 2024

The poster introduces Anocca’s programmable cellular technology platform that systematically recreates human T-cell biology to map T-cell targets and build TCR libraries for the generation of validated therapeutic TCRs, and describes the preclinical development of its lead therapeutic TCR-T product targeting KRAS-G12V that is being progressed into planned clinical trials.
go to media item
License:
All rights reserved
The Content may only be used by Mynewsdesk. It is thus not permissible for anyone else to download, copy, distribute or otherwise use the Content (other than for private use to the extent permitted by law).
File format:
.pdf

Topics

Categories

Contacts

  • Zach Chia

    Zach Chia

    Press contact VP, Strategy & Business Development Business Development, External Communications

Related content

  • Anocca Presents Data at ESMO Congress on Preclinical Development of its TCR-T Cell Therapies for Cancer

    Anocca Presents Data at ESMO Congress on Preclinical Development of its TCR-T Cell Therapies for Cancer

    SÖDERTÄLJE, SWEDEN, 9 Sept 2024 – Anocca AB, a leading T cell receptor-engineered T cell (TCR-T) cellular therapeutics company, announces it will present its novel platform approach to therapeutic TCR discovery and preclinical data for its lead TCR-T cell therapy product at the European Society of Medical Oncology (ESMO) Congress 2024.

    Category: Investigational Immunology
    Poster title: P